newsfilter
← Latest News
GlobeNewswire·

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

ZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases,